In four pediatric T1D registries, prevalence of overweight/obesity ranged from 15.3% in Germany/Austria during 1995-2011 to 36.0% in the United States during 2016-2018
A questionnaire inquiring about the duration and frequency of the halitosis, and a detailed medical and dental history, with plaque control regimen, has to be recorded
For practices looking to improve patient engagement and outreach, digital tools can make a difference
Why your prescription purpose doesnt disqualify you: The injury is the same whether you took the drug for diabetes or weight loss The warnings were inadequate for both approved uses The mechanism is identical regardless of indication The failure to warn affected all patients, not just one category In fact, diabetes patients may have stronger arguments: You needed the medication for a serious health condition You had fewer alternatives available The risk-benefit calculation was different You were a captive market with less choice Your claim will focus on: Whether you were adequately informed of gastroparesis risk Whether the severity and potential permanence were disclosed Whether you would have chosen differently if properly warned The damages you suffered as a result Q: What if I took multiple GLP-1 drugs over time
For readers who want a broader look at how TrimRx approaches access and treatment decisions, our Introduction to TrimRx offers a helpful overview of the program and its telehealth approach
The Precision Peptide Genetic Test reveals variants in key pathways (GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that may influence your medication response and optimal dosing protocol
